Floatz logo

URSODEOXYCHOLIC ACID

Nonalcoholic Steatohepatitis (NASH)

Kafrelsheikh UniversitySmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Nonalcoholic Steatohepatitis (NASH) cohort.

Asset / SponsorPhaseRating
zsp1601
Guangdong Raynovent Biotech Co., Ltd
Phase 2BB
hec96719
Sunshine Lake Pharma Co., Ltd.
Phase 2BB
Cilofexor
Gilead Sciences
Phase 2B
Arachidyl amido cholanoic acid
Galmed Research and Development, Ltd.
Phase 3B
Miricorilant
Corcept Therapeutics
Phase 2B

View all 17 →

Same molecule, other indications

URSODEOXYCHOLIC ACID is also rated in:

primary biliary cholangitisDormant
A
Indicative ·
82 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
Nonalcoholic Fatty Liver Disease (NAFLD)Dormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →